investigating the efficacy of cognitive behavioral therapy in patients with substance use disorder and comorbid ADHD. A randomized controlled trial with cognitive behavioral therapy.

Completed

• Conditions: verslaving; ADHD; attention-deficit hyperactivity disorder; 10009841

• Registration Number: NL-OMON37930
• Lead Sponsor: Arkin (Amsterdam)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

- age 18-60 years
- current DSM-IV diagnosis of adult ADHD
- current DSM-IV diagnosis of Substance Use Disorder
- able to provide written informed consent and to comply with all study procedures.

Exclusion Criteria

- severe neurological or psychiatric disorders (e.g. Parkinson's disease, dementia, epilepsy, psychosis, bipolar depression) that require psychotropic medications.
- inability to read/ write Dutch language

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>During the trial, the Dutch version of the ADHD rating scale will be completed<br /><br>three times (at the start of the trial, at the end, and at follow-up (3 months<br /><br>after the last CBT session). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- TLFB (Time Line Follow Back): self-report measure for substance use<br /><br>- Beck Depression Inventory (BDI)<br /><br>- Beck Anxiety Inventory (BAI)<br /><br>- EQ-5: quality of life<br /><br>- TIC-P (health care consumption and production losses)<br /><br>- neurocognitive task: Stroop<br /><br>- Urine checks (cocaine, amphetamines, XTC, opioids, cannabis, benzodiazepines,<br /><br>alcohol)</p><br>